Tags

Type your tag names separated by a space and hit enter

Quetiapine modulates conditioned anxiety and alternation behavior in Alzheimer's transgenic mice.
Curr Alzheimer Res. 2013 Feb; 10(2):199-206.CA

Abstract

Quetiapine, an atypical antipsychotic drug, is effective in treating the behavioral and psychological symptoms in Alzheimer's disease (AD). However, it is presently unclear whether quetiapine has beneficial effects on memory and whether the effects of quetiapine on psychological symptoms are associated with its effect on memory in AD. The present study was designed to examine the effect of chronic administration of quetiapine on the conditioned (generalized) anxiety that is related to learning experience of open arm exposure in the elevated T-maze (ETM) test in an amyloid precursor protein (APP)/presenilin 1 (PS1) double transgenic mouse model of AD. In a 2nd experiment, the effect of quetiapine on memory per se was investigated in a Y-maze test in AD mice. Non-transgenic and transgenic mice were treated with quetiapine in drinking water from the age of 2 months. After continuous treatment with quetiapine (5 mg/kg/day) for 10 months, mice were tested for conditioned anxiety on the ETM task. After ETM testing, the expression of brain-derived neurotrophic factor (BDNF), a neuroprotective protein, was examined by immunohistochemistry in the basolateral amygdala (BLA) and hippocampus. In the 2nd experiment, the effect of quetiapine (2.5 or 5 mg/kg/day) on the short-term memory in AD mice was tested in a Y-maze test. After 10 months of administration, quetiapine prevented the decrease of conditioned anxiety and cerebral BDNF in AD mice. In addition, quetiapine also prevented memory impairment in the Y-maze test in AD mice. These findings suggest that the therapeutic mechanism of quetiapine on anxiety in AD may be associated with its beneficial effect on memory and its neuroprotective effect on cerebral BDNF expression.

Authors+Show Affiliations

Department of Psychiatry, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22950914

Citation

Tempier, Adrien, et al. "Quetiapine Modulates Conditioned Anxiety and Alternation Behavior in Alzheimer's Transgenic Mice." Current Alzheimer Research, vol. 10, no. 2, 2013, pp. 199-206.
Tempier A, He J, Zhu S, et al. Quetiapine modulates conditioned anxiety and alternation behavior in Alzheimer's transgenic mice. Curr Alzheimer Res. 2013;10(2):199-206.
Tempier, A., He, J., Zhu, S., Zhang, R., Kong, L., Tan, Q., Luo, H., Kong, J., & Li, X. M. (2013). Quetiapine modulates conditioned anxiety and alternation behavior in Alzheimer's transgenic mice. Current Alzheimer Research, 10(2), 199-206.
Tempier A, et al. Quetiapine Modulates Conditioned Anxiety and Alternation Behavior in Alzheimer's Transgenic Mice. Curr Alzheimer Res. 2013;10(2):199-206. PubMed PMID: 22950914.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quetiapine modulates conditioned anxiety and alternation behavior in Alzheimer's transgenic mice. AU - Tempier,Adrien, AU - He,Jue, AU - Zhu,Shenghua, AU - Zhang,Ruiguo, AU - Kong,Lynda, AU - Tan,Qingrong, AU - Luo,Huanmin, AU - Kong,Jiming, AU - Li,Xin-Min, PY - 2012/11/14/received PY - 2012/05/22/revised PY - 2012/07/17/accepted PY - 2012/9/7/entrez PY - 2012/9/7/pubmed PY - 2013/9/7/medline SP - 199 EP - 206 JF - Current Alzheimer research JO - Curr Alzheimer Res VL - 10 IS - 2 N2 - Quetiapine, an atypical antipsychotic drug, is effective in treating the behavioral and psychological symptoms in Alzheimer's disease (AD). However, it is presently unclear whether quetiapine has beneficial effects on memory and whether the effects of quetiapine on psychological symptoms are associated with its effect on memory in AD. The present study was designed to examine the effect of chronic administration of quetiapine on the conditioned (generalized) anxiety that is related to learning experience of open arm exposure in the elevated T-maze (ETM) test in an amyloid precursor protein (APP)/presenilin 1 (PS1) double transgenic mouse model of AD. In a 2nd experiment, the effect of quetiapine on memory per se was investigated in a Y-maze test in AD mice. Non-transgenic and transgenic mice were treated with quetiapine in drinking water from the age of 2 months. After continuous treatment with quetiapine (5 mg/kg/day) for 10 months, mice were tested for conditioned anxiety on the ETM task. After ETM testing, the expression of brain-derived neurotrophic factor (BDNF), a neuroprotective protein, was examined by immunohistochemistry in the basolateral amygdala (BLA) and hippocampus. In the 2nd experiment, the effect of quetiapine (2.5 or 5 mg/kg/day) on the short-term memory in AD mice was tested in a Y-maze test. After 10 months of administration, quetiapine prevented the decrease of conditioned anxiety and cerebral BDNF in AD mice. In addition, quetiapine also prevented memory impairment in the Y-maze test in AD mice. These findings suggest that the therapeutic mechanism of quetiapine on anxiety in AD may be associated with its beneficial effect on memory and its neuroprotective effect on cerebral BDNF expression. SN - 1875-5828 UR - https://www.unboundmedicine.com/medline/citation/22950914/Quetiapine_modulates_conditioned_anxiety_and_alternation_behavior_in_Alzheimer's_transgenic_mice_ DB - PRIME DP - Unbound Medicine ER -